IEX •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization88.38 mln
Float51.88 mln
Earnings Date07/31/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
6.60
Transformational upside
Relative Strength
38
/ 100
Underperforming
Debt / Equity
0.37
Low leverage
ROE
-53.76
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aldeyra Therapeutics is a Massachusetts-based biotech company focused on developing treatments for immune-related conditions. Its most advanced drug candidates include reproxalap, currently in late-stage trials for dry eye disease and eye allergies, and ADX-2191, targeting rare eye cancers and inherited retinal disorders. The company is also testing an oral drug, ADX-629, across a range of conditions including asthma, psoriasis, and COVID-19, while continuing to advance several earlier-stage compounds built on the same core science.
